View Older Stories View More Recent Stories
-
Disney (DIS): Cutting PT On Loss Of Visibility - BMO
-
Alder Biopharm (ALDR) PT Lowered to $27 at BMO Capital
-
BMO Capital Downgrades Monogram Residential Trust (MORE) to Market Perform
-
MyoKardia (MYOK) Prices 3.5M Share Offering at $35/Sh
-
BMO Capital Downgrades Starbucks (SBUX) to Market Perform
-
MyoKardia Announces Pricing of Public Offering of Common Stock
-
Swiss franc, yen rise as North Korea tensions brew
-
Horizon Pharma (HZNP) PT Raised to $18 at BMO Capital on 2Q Beat; 'Nice Reovery in 2Q... Raised Guidance Appears Conservative'
-
Tyson (TSN) PT Raised to $78 at BMO Capital on 3Q Beat; 'Fundamental Margin Structure Outlook Across Chicken, Beef & Pork Remains Favorable'
-
2U, Inc. (TWOU) PT Raised to $56 at BMO Capital on 2Q Beat; '2017 Guidance Raised for Impact of GetSmarter'
-
Coherus Biosciences (CHRS) PT Lowered to $38 at BMO Capital; 'Refiling of Neulasta Biosimilar Remains on Track for 4Q17'
-
Genesis Energy, L.P. Prices Public Offering of Senior Notes
-
BMO Capital Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
-
Ares Capital Corporation Prices Public Offering of $750.0 Million 3.500% Notes Due 2023
-
MyoKardia (MYOK) Commences 3.5M Offering of Common Stock
-
MyoKardia Announces Proposed Public Offering of Common Stock
-
UPDATE: MyoKardia (MYOK) PT Raised to $45 at BMO Capital
-
Genesis Energy, L.P. Announces Public Offering of Senior Notes
-
BMO Capital Upgrades Extraction Oil & Gas (XOG) to Outperform
-
BMO Capital Upgrades B&G Foods (BGS) to Outperform
-
Arista Networks (ANET) PT Raised to $190 at BMO Capital on 2Q Report; 'Demand was Broad-Based Across Verticals
-
B&G Foods (BGS) PT Lowered to $39 at BMO Capital on 2Q Miss; 'Base Business Remains Among Weakest Product Segments in U.S. Food Industry'
-
Splunk (SPLK) PT Lowered to $69 at BMO Capital; 'Ongoing Slowdown in Billings Growth Rates'
-
Synaptics (SYNA) PT Lowered to $46 at BMO Capital on 2Q Report; 'Core Business Deteriorating Faster Than We Thought'
-
Viacom (VIAB) PT Lowered to $35 at BMO Capital on 2Q Report; 'Affiliate Fee Outlook Remains Challenging'
-
Kellogg (K) PT Lowered to $78 at BMO Capital on 2Q; 'Reduce 2018 Estimates on Ongoing Macro Challenges'
-
Canada trade deficit swells in June, but hiring continues in July
-
ADP (ADP) Should Respond Favorably To Comments Bill Ackman Wants Control Of Company - BMO Capital
-
Jazz (JAZZ) Vyxeos Approval Earlier than Expected, with No Age Restrictions - BMO
-
BMO Financial Group Receives 2017 Thomson Reuters/S-Network ESG Best Practices Award
-
Norbord (OSB) 3.55M Shares from Brookfield Offered at $42.35/Share
-
AK Steel Announces Pricing of $280,000,000 of Senior Notes due 2025
-
Norbord Inc. Announces Secondary Bought Deal Offering of Its Common Shares by Brookfield
-
Resolute Energy Corporation Announces Appointment of Tod Benton and Janet Pasque to Board of Directors
-
National Storage Affiliates Trust Reports Second Quarter 2017 Results; Net Income Increases $9.6 Million; Core FFO Per Share Increases 10.7%; Same Store NOI Increases 8.4%; Acquired 10 Self Storage Pr
-
Last Week's Best Performing Shorts - S3
-
Spark Therapeutics (ONCE) PT Raised to $89 at BMO Capital
-
Bright Horizons (BFAM) PT Raised to $85 at BMO Capital on 2Q Report; 'Organic Growth Improved'
-
FireEye, Inc (FEYE) PT Raised to $17 at BMO Capital on 2Q Report; 'Position with Customers Continues to Improve'
-
DexCom (DXCM) PT Lowered to $90 at BMO Capital Following 2Q on 'Near-Term Medicare Reimbursement Disruption'
-
StreetInsider.com Premium Hot Research Recap 08/02
-
Mosaic (MOS) PT Lowered to $25 at BMO Capital on 2Q Report; 'Phosphate Margin Squeeze... On Weak Fundamentals'
-
AK Steel Announces Offering of $280,000,000 of Senior Notes and Cash Tender Offer for its 8.375% Senior Notes due 2022
-
BMO Capital Upgrades Pfizer (PFE) to Outperform
-
Apple (AAPL) PT Raised to $180 at BMO Capital
-
Kosmos Energy Announces Intention to Pursue Secondary Listing on the London Stock Exchange
-
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intercept Pharmaceuticals (ICPT) PT Raised to $221 at BMO Capital on 2Q Report; 'Solid 2Q17 Earnings + Two Positive Phase 2 Readouts... Buy on Weakness'
-
Fiserv (FISV) PT Raised to $133 at BMO Capital Ahead of 2Q Report Today AMC; 'Slight EPS Beat Expected on Margin Expansion with Scale'
-
AGCO Corporation (AGCO) PT Raised to $75 at BMO Capital on 2Q Report; 'Operating at a High Level... Outperformance Continues from European Segment'
